Hereditary Angioedema due to C1 Inhibitor Deficiency: C1-INH Replacement Therapy

Mauro Cancian

DOI: https://doi.org/10.7175/rhc.v5i2.913

Abstract

Hereditary angioedema (HAE) is a rare condition affecting about 1 in 50.000 individuals and caused by a mutation in the gene encoding the C1-esterase inhibitor (C1-INH), which is involved in the control of complement, clotting, fibrinolytic and kinin pathways. HAE is characterized by plasma outflow from blood vessels, leading to fluid collecting (edema) in the deep tissue layers of the face, larynx, abdomen, and extremities. Three different types of HAE have been identified: in type I the mutation leads to the lack of production of C1-INH, in type II the mutation leads to the production of dysfunctional C1-INH, while type III is extremely rare and still not fully understood. Therapeutic approaches for HAE include on-demand treatments to stop angioedema attacks and prophylactic treatment to prevent attacks both by pre-procedural (short-term) and routine (long-term) prophylaxis. Aim of the present review is to present an overview of C1-INH replacement therapy with the plasma-derived concentrate of C1-INH Berinert® (CSL Behring GmbH) in the treatment of type I and II HAE.

Keywords

Hereditary angioedema; C1 inhibitor deficiency; Replacement therapy

Full Text

HTML PDF

References

  • Carr TF, Saltoun CA. Urticaria and Angioedema. Allergy asthma Proc 2012; 33(S1): S70-2; http://dx.doi.org/10.2500/aap.2012.33.3554
  • Cicardi M, Bellis P, Bertazzoni G, et al. Guidance for diagnosis and treatment of acute angioedema in the emergency department: consensus statement by a panel of Italian experts. Intern Emerg Med 2014; 9: 85-92; http://dx.doi.org/10.1007/s11739-013-0993-z
  • Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angio-oedema. Lancet 1998; 351: 1693-7; http://dx.doi.org/10.1016/S0140-6736(97)09137-X
  • Davis AE 3rd. Hereditary angioedema: a current state-of-the-art review, III: mechanisms of hereditary angioedema. Ann Allergy Asthma Immunol 2008; 100: 7-12; http://dx.doi.org/10.1016/S1081-1206(10)60580-7
  • Cugno M, Zanichelli A, Foieni F, et al. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med 2009; 15: 69-78; http://dx.doi.org/10.1016/j.molmed.2008.12.001
  • Kaplan AP, Joseph K. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway. Adv Immunol 2014; 121: 41-89; http://dx.doi.org/10.1016/B978-0-12-800100-4.00002-7
  • Agostoni A, Aygören-Pürsün E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004; 8(S3): S51–S131; http://dx.doi.org/10.1016/j.jaci.2004.06.047
  • Zuraw BL. Hereditary angioedema. N Engl J Med 2008; 359: 1027-36; http://dx.doi.org/10.1056/NEJMcp0803977
  • Vasekar M, Craig TJ. ACE inhibitor-induced angioedema. Curr Allergy Asthma Rep 2012; 12: 72-8; http://dx.doi.org/10.1007/s11882-011-0238-z
  • Beltrami L, Zanichelli A, Zingale L, et al. Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema. J Hypertens 2011; 29: 2273-7; http://dx.doi.org/10.1097/HJH.0b013e32834b4b9b
  • Cicardi M, Zanichelli A. The acquired deficiency of C1-inhibitor: lymphoproliferation and angioedema. Curr Mol Med 2010; 10: 354-60; http://dx.doi.org/10.2174/156652410791317066
  • Bork K. Hereditary angioedema with normal C1 inhibitor activity including hereditary angioedema with coagulation factor XII gene mutations. Immunol Allergy Clin North Am 2006; 26: 709-24; http://dx.doi.org/10.1016/j.iac.2006.09.003
  • Zuraw BL, Bork K, Binkley KE, et al. Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. Allergy Asthma Proc. 2012; 33(S1): S145-56; http://dx.doi.org/10.2500/aap.2012.33.3627
  • Nzeako UC, Longhurst HJ. Many faces of angioedema: focus on the diagnosis and management of abdominal manifestations of hereditary angioedema. Eur J Gastroenterol Hepatol 2012; 24: 353-61
  • Cancian M, Vettore G, Realdi G. An uncommon case of acute pancreatitis. Gastroenterology 2011; 140: 33, 370
  • Arcoleo F, Bova M, Cancian M, et al. Angioedema ereditario da carenza di C1 inibitore. Consensus Document italiano per la diagnosi e la terapia. Giorn It Allergol Immunol Clin 2008: 18: 114-22
  • Bowen T, Cicardi M, Farkas H, et al 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010; 6: 24; http://dx.doi.org/10.1186/1710-1492-6-24
  • Tarzi MD, Hickey A, Forster T, et al. An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angioedema: assay evaluation and reccomandations. Clin Exp Immunol 2007; 149: 513-6; http://dx.doi.org/10.1111/j.1365-2249.2007.03438.x
  • Ebo DG, Kathleen J, De Knop KJ, et al. Hereditary Angioedema in Childhood. An Approach to Management. Pediatr Drugs 2010; 12: 257-68; http://dx.doi.org/10.2165/11532590-000000000-00000
  • Craig T, Pursun EA, Bork K, et al. WAO guidelines for the management of Hereditary angioedema. WAO Journal 2012; 5: 182-99
  • Cicardi M, Bork K, Caballero T, et al. Evidence-based reccomandations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012; 67: 147-57; http://dx.doi.org/10.1111/j.1398-9995.2011.02751.x
  • Wahn V, Aberer W, Ebert W, et al. Hereditary angioedema (HAE) in children and adolescents – a consensus on therapeutic strategies. Eur J Pediatr 2012; 171: 1339-48; http://dx.doi.org/10.1007/s00431-012-1726-4
  • Cicardi M, Craig TJ, Martinez-Saguer I, et al. Review of recent guidelines and consensus statements on hereditary angioedema therapy with focus on self-administration. Int Arch Allergy Immunol 2013; 161: S3-9; http://dx.doi.org/10.1159/000351232
  • Pickering RJ, Good RA, Kelly JR, et al. Replacement therapy in hereditary angioedema. Successful treatment of two patients with fresh frozen plasma. Lancet 1969; 1: 326-30; http://dx.doi.org/10.1016/S0140-6736(69)91295-1
  • Keating GM. Human C1-Esterase Inhibitor Concentrate (Berinert). Biodrugs 2009; 23: 399-406; http://dx.doi.org/10.2165/11201100-000000000-00000
  • De Serres J, Gröner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. Transfus Apher Sci 2003; 29: 247-54; http://dx.doi.org/10.1016/j.transci.2003.08.006
  • Groner A, Nowak T, Schafer W. Pathogen safety of human C1 esterase inhibitor concentrate. Transfusion 2012; 52: 2104-12; http://dx.doi.org/10.1111/j.1537-2995.2012.03590.x
  • Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared to placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009; 124: 801-8; http://dx.doi.org/10.1016/j.jaci.2009.07.017
  • Craig TJ, Bewtra AK, Bahna SL, et al. C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks - final results of the I.M.P.A.C.T.2 study. Allergy 2011; 66: 1604-11; http://dx.doi.org/10.1111/j.1398-9995.2011.02702.x
  • Bork K, Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med. 2001; 161: 714-8; http://dx.doi.org/10.1001/archinte.161.5.714
  • Schneider L, Hurewitz D, Wasserman R, et al. C1-INH concentrate for treatment of acute hereditary angioedema: a pediatric cohort from the I.M.P.A.C.T. Studies. Pediatr Allergy Immunol 2013: 24: 54-60; http://dx.doi.org/10.1111/pai.12024
  • Hack CE, Relan A, van Amersfoort ES, et al. Target levels of functional C1-inhibitor in hereditary angioedema. Allergy 2012; 67: 123-30; http://dx.doi.org/10.1111/j.1398-9995.2011.02716.x
  • Bork K, Steffensen I, Machnig T. Treatment with C1-esterase inhibitor concentrate in type I or II hereditary angioedema: a systematic literature review. Allergy Asthma Proc 2013; 34: 312-27; http://dx.doi.org/10.2500/aap.2013.34.3677
  • Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol 2012; 129: 308-20; http://dx.doi.org/10.1016/j.jaci.2011.11.025
  • Longhurst HJ, Carr S, Khair K. C1-inhibitor concentrate home therapy for hereditary angioedema:
  • a viable, effective treatment option. Clin Exp Immunol 2006; 147: 11-7
  • Bygum A, Andersen KE, Mikkelsen CS. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol 2009; 19: 147-51
  • Kreuz W, Rusicke E, Martinez-Saguer I, et al. Home therapy with intravenous human C1-inhibitor in children and adolescents with hereditary angioedema. Transfusion 2012; 52: 100-7; http://dx.doi.org/10.1111/j.1537-2995.2011.03240.x
  • Zuraw BL, Busse PJ, Jacobs J, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010; 363: 513-22; http://dx.doi.org/10.1056/NEJMoa0805538
  • Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010; 126: 821-7; http://dx.doi.org/10.1016/j.jaci.2010.07.021
  • Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010; 363: 532-41; http://dx.doi.org/10.1056/NEJMoa0906393
  • Bork K, Hardt J, Staubach-Renz P, et al. Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011; 112: 58-64; http://dx.doi.org/10.1016/j.tripleo.2011.02.034
  • Farkas H, Zotter Z, Csuka D, et al. Short-term prophylaxis in hereditary angioedema due to deficiency of the C1-inhibitor - a long-term survey. Allergy 2012; 67: 1586-93
  • Farkas H, Varga L, Szeplaki G, et al. Management of hereditary angioedema in pediatric patients. Pediatrics 2007; 120: 713-22; http://dx.doi.org/10.1542/peds.2006-3303
  • Frank MM, Sergent JS, Kane MA, et al. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med 1976; 295: 1444-8; http://dx.doi.org/10.1056/NEJM197612232952602
  • Bork K, Bygum A, Hardt J. Benefits and risk of danazol in hereditary angioedema: a long term survey of 118 patients. Ann Allergy Asthma Immunol 2008; 100: 153-61; http://dx.doi.org/10.1016/S1081-1206(10)60424-3

Statistics

Abstract: 1206 views
HTML: 1790 views
PDF: 574 views

Refbacks

  • There are currently no refbacks.




© SEEd srl